1.Ankle Fracture
Kong Woong KWON ; Myung Sang MOON
The Journal of the Korean Orthopaedic Association 1972;7(3):303-311
One hundred and four cases of the ankle fracture have been treated and managed in the Department of Orthopaedic Surgery, Catholic Medical College Hospital. During the period from January, 1968 to December, 1971. 104 patients were analyzed clinically and the results obtained were as follow. 1. The causes of ankle fractures were mostly due to traffic accident 49.9% and direct blow 30.7%. 2. The incidence of trauma was in the young man, most frequent in the 3rd decaed. 3. In classification of Lauge-Hansen, the type of pronation-external rotation is most common type in this series and the stage III of pronation-external rotation is more common than other stages. 4. The average duration of cast immobilization is 8.8 weeks after closed reduction performed but duration of cast immobilization is shorter after open reduction of cast immobilization. 5. Anatomical reduction was obtained in 64 patients 61.5% with good objective clinical results in 54 patients 51.9% 6. The quality of clinical results depends mostly on the accuracy of the reduction, to a lesser extent on the degree of initial displacements, and least on the type of fracture.
Accidents, Traffic
;
Ankle Fractures
;
Ankle
;
Classification
;
Humans
;
Immobilization
;
Incidence
2.Familial Metaphyseal Dysplasia: Report 2 Cases
Kong Woong KWON ; Tae Sung CHUNG
The Journal of the Korean Orthopaedic Association 1972;7(4):469-472
Authors present two casas of familial metaphyseal dysplasia which was first described by Pyle as a skeletal disorder affecting the metaphyseal region of tubular bones. The cases reported here bear some resemblance to that of Bawkin and Krida.
3.The Quantitative Analysis of Effectiveness of Radiation Therapy on Choroidal Ne ovascular Membra n e s.
Ha Young KONG ; Yong Su CHO ; Soon Hyun KIM ; Oh Woong KWON ; Chang Ok SUH ; Jihoon LIM ; Jae Ho CHO
Journal of the Korean Ophthalmological Society 2000;41(6):1364-1372
The natural course of visual acuity of choroidal neovascularization (CNV) membrane is known to be poor.When fovea is involved, only a subset of patients is eligible for laser photocoagulation or alternative treatment odalities.Radiation therapy has been investigated for applying to such cases, however there have been controversies among reports on the effec-tiveness of radiation therapy.Hence we intended to evaluate the effective-ness of radiation therapy quantitatively.Twenty-one eyes with subfoveal CNV were treated with 4 MV X-ray (total dose of 20 Gy).After the follow-up period of 6months or longer, the visual acuity remained stable or improved from the initial visual acuity in 15 of 21 eyes (71.4%). Based on indocyanine green (ICG)video angiography, the CNVs decreased in their size in 16 of 21 eyes (76.2%)and this difference was statistically significant. These results suggest that radiation can induce regression of subfoveal CNV and maintain central vision in a significant number of patients and we believe that larger, longer study is necessary.
Angiography
;
Choroid*
;
Choroidal Neovascularization
;
Follow-Up Studies
;
Humans
;
Indocyanine Green
;
Light Coagulation
;
Membranes
;
Visual Acuity
4.Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3
Jung-Yun LEE ; Yoo-Young LEE ; Jeong-Yeol PARK ; Seung-Hyuk SHIM ; Se Ik KIM ; Tae-Wook KONG ; Chul Kwon LIM ; Hyun Woong CHO ; Dong Hoon SUH
Journal of Gynecologic Oncology 2023;34(2):e51-
In the 2022 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Ovarian cancer: long-term follow-up data, new poly (ADP-ribose) polymerase (PARP) inhibitors, overall survival (OS) issues with PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugate; 2) Cervical cancer: surgery in early stage disease, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Corpus cancer: follow-up regimen, immune checkpoint inhibitor, WEE1 inhibitor, selective inhibitor of nuclear export. A special note was made on the withdrawal of PARP inhibitor from the market for heavily pretreated ovarian cancer patients based on the final OS results of ARIEL-4 and SOLO-3 due to concerns of increased risk of death.